Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
RESEARCH TOOLSreports
AN2 Therapeutics, Inc. (ANTX) Stock Price & Analysis
63 Followers
ANTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.20 - $22.22
Previous Close$2.31
Volume76.77K
Average Volume (3M)342.05K
Market Cap
$68.91M
Enterprise Value-$54.90M
Total Cash (Recent Filing)$123.80M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.8
Beta1.67
Next Earnings
Aug 08, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.82
Shares Outstanding29,770,375
10 Day Avg. Volume92,807
30 Day Avg. Volume342,050
Standard Deviation0.38
R-Squared0.00005
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$5.50Price Target Upside138.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
AN2 Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst initiates coverage of AN2 Therapeutics with a Market Outperform rating and a $30 price target, and another upgrade to Market Outperform with a new $6 price target, reflecting potential undervaluation at current levels.
Drug DevelopmentEpetraborole may become the first FDA-approved oral option for refractory MAC NTM lung disease, showing robust activity in vitro and in NTM models, which indicates a higher likelihood of clinical success.
Financial StabilityAN2 Therapeutics has a substantial cash position, believed to be sufficient for at least 12 months of operations, providing financial stability in the short term.
Bears Say
Clinical TrialsVoluntary pausing of enrollment in Phase 3 trial for epetraborole due to potentially low efficacy.
Drug EfficacyEpetraborole efficacy called into question; downgrading to Market Perform.
Regulatory ApprovalLowered probability of approval for epetraborole in refractory MAC NTM to 25%.
---
Ownership Overview
42.82% Insiders
5.48% Mutual Funds
3.86% Other Institutional Investors
47.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $2.20 and its highest was $22.22 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
Currently, no data Available
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Aug 08, 2024 which is in 85 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on May 08, 2024. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.62 by $0.06.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -$0.63.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,829,040 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.62. Following the earnings report the stock price went down -4.314%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Among the largest hedge funds holding AN2 Therapeutics, Inc.’s share is RA Capital Management. It holds AN2 Therapeutics, Inc.’s shares valued at 114M.
---
AN2 Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (138.10% Upside)
$5.50 (138.10% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.61%
12-Months-Change
Fundamentals
Return on Equity
-58.83%
Trailing 12-Months
Asset Growth
35.28%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Month Forecast
Average Price Target
$5.50
▲(138.10% Upside)
Technical Analysis
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-52.30%
reiterated a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.30% per trade.
---